Innate lymphoid cells (ILCs) belong to an emerging family of innate immune cells that have been implicated in playing critical roles in human health and disease. This SnapShot summarizes current knowledge on the development of various ILC populations in humans and mice (boxes 1 and 2) and the regulation and function of these cells in different tissues (boxes 3-7).
Development and Heterogeneity of Innate Lymphoid Cells
We hypothesize that the various groups of ILCs develop from a CD127 interleukin-7Rα (IL-7Rα)
+ common lymphoid precursor(s) that might depend on the transcriptional repressor Id2, but unlike T cells and B cells, this occurs independently of somatic recombination of antigen-specific receptors (box 1). Mature ILC populations can be divided into three groups based on shared phenotypic and functional properties (box 1). Group 1 ILCs (ILC1s) constitutively express T-bet and are able to produce interferon-γ (IFN-γ) upon activation. ILC1s include classical natural killer (NK) cells that depend on IL-15 and the transcription factors Nfil3, Eomesodermin, and T-bet for differentiation and maturation. ILC1s also include both CD127
− and CD127 + non-NK cells that are poorly defined. CD127 − ILC1s reside in the intestinal epithelium and depend on T-bet and Nfil3 for development but are independent of IL-15. The developmental pathways of CD127 + ILC1s are not fully elucidated, but they likely depend on IL-7 and T-bet. Group 2 ILCs (ILC2s) depend on Notch, TCF1, RORα, GATA-3, and IL-7 for development. ILC2s constitutively express GATA-3 and in response to IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) stimulation produce IL-5, IL-13, and amphiregulin (Areg). Mouse ILC3s develop from two distinct progenitors. The α4β7 + progenitors depend on Notch and IL-7, but Notch needs to be downregulated in these cells before they differentiate into CCR6 + , T-bet − ILC3s, which include lymphoid tissue inducer (LTi) cells and are heterogeneous in expression of CD4. The a4β7 − progenitors depend on Notch, IL-7, and the aryl hydrocarbon receptor (AhR) for differentiation into CCR6 − , T-bet + ILC3s that are natural cytotoxicity receptor (NCR − ) and can further differentiate into NCR + ILC3s. All ILC3s constitutively express and depend on the transcription factor RORγt for development, and in response to IL-1β, IL-23, and AhR, agonists produce IL-17, IL-22, and/or IFN-γ.
Comparison of Human and Mouse ILCs
Critically, ILC1s, ILC2s, and ILC3s exhibit conserved phenotypic properties across mammalian species (box 2). Comparative analyses of human and mouse ILCs have revealed consistent expression of common cytokine receptors, such as CD127 (IL-7Rα) on all ILC subsets, IL-12RB2 on ILC1s, IL-25R (IL-17RB) and IL-33R (ST2) on ILC2s, and IL-23R on ILC3s. However, several notable differences exist in the comparison of ILC groups between humans and mice. For example, a subset of mouse ILC3s expresses CD4, whereas human ILCs do not, and all human ILC3s express CCR6 in comparison to only a subset of mouse ILC3s. The NCRs expressed by ILC3s are also different between humans and mice because NKp46 is expressed by both species, but NKp44 is expressed only in humans. Furthermore, whereas CRTH2 is selectively expressed on human ILC2s, mouse ILC2s seem to be less well defined by this receptor.
Tissue-Specific Functions of Innate Lymphoid Cells
The regulation and function of ILCs occurs in a tissue-specific context (boxes 3-7). In the skin (box 3), a challenge with an allergen or inflammatory stimuli can elicit ILC2 or ILC3 responses. ILC2 responses in the skin can be regulated by epithelial cell-derived TSLP and IL-2 (from an undefined cellular source) and might promote allergic inflammation through potential interactions with mast cells via IL-13 or direct regulation of keratinocytes via IL-13 or amphiregulin. In contrast, ILC3 responses in the skin contribute to epidermal thickening via production of IL-22, likely induced by expression of IL-1β and IL-23. Lung-residing ILC2s (box 4) have the capacity to respond to protease allergens, infection with influenza, or the parasite Nippostrongylus brasiliensis, and activated ILC2s have been observed in bronchial lavage of asthmatic patients. ILC2 responses are elicited by epithelial cell-derived IL-25, IL-33, and TSLP and myeloid cell-derived IL-33. Intriguingly, in asthmatic patients, the mast cell product prostaglandin D2 (PGD 2 ) increases, while Lipoxin A4 (LXA 4 ) from an unidentified cellular source limits cytokine production by ILC2s. ILC2s can regulate airway immunity and inflammation through IL-5-and IL-13-mediated recruitment and activation of eosinophils and alternatively activated macrophages (AAMac), IL-13-mediated induction of airway hyperresponsiveness (AHR), or amphiregulinmediated repair of the airway epithelium.
In the intestine (box 5), ILC1, ILC2, and ILC3 responses have been observed. During homeostasis, ILC3s promote tissue repair, anatomical containment of commensal bacteria, and protection against pathogenic bacteria via production of IL-22. ILC3 responses can be elicited in response to commensal and pathogenic bacteria or other inflammatory stimuli via myeloid cell-derived IL-1β and IL-23 and can be suppressed through regulation of myeloid cell responses by IL-25. Furthermore, ILC3s can promote inflammationdependent colitis via production of IL-17 and contribute to colitis-associated cancer progression through IL-22. Similar to the lung, ILC2s in the intestine are elicited by parasitic infection in response to epithelial cell-derived IL-25 and IL-33 and can promote immunity through IL-13-mediated goblet cell responses and mucus production. In Crohn's disease, epithelium-residing CD127 − ILC1s and lamina propria-residing CD127 + ILC1s respond to IL-12 and produce IFN-γ, and they likely contribute to the inflammatory responses. Further studies suggest that a subset of CD127 + ILC1s might differentiate from ILC3s after downregulation of RORγt expression in response to infectious or inflammatory stimuli (data not shown).
ILCs can also orchestrate immune responses in other tissues (boxes 6 and 7). A subset of ILC3s, known as LTi cells, promotes the prenatal organogenesis of lymph nodes and Peyer's patches through expression of lymphotoxin β (LTβ) that acts on resident stromal cells and recruits additional lymphoid cells, including B cells and myeloid cells. Furthermore, LTi-like ILC3s are also critical for the development, maintenance, and repair of postnatal lymphoid tissues via LTβ or IL-22. These pathways are critical to maintain functions of lymphoid organs such as the spleen, thymus, and isolated lymphoid follicles after infectious and inflammatory challenge (data not shown). LTi-like ILC3s also regulate CD4 + T cell responses through direct regulation of commensal bacteria-responsive CD4 + T cells via MHCII or maintenance of memory CD4 + T cell populations via CD30L and OX40L. Finally, ILC2s are also present in adipose tissues and play a critical role in the maintenance of tissue-resident eosinophils and AAMacs, two cell types implicated in the regulation of metabolic homeostasis.
